ERASCA INC (ERAS) Stock News
NASDAQ:ERAS - Nasdaq - US29479A1088 - Common Stock - Currency: USD
ERAS Latest News, Press Relases and Analysis
Erasca to Present at the Bank of America Securities Health Care Conference
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering,...
Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting
ERAS-0015 and ERAS-4001 showed robust anti-tumor activity as monotherapy and combination therapy First-in-class examples of direct SHOC2 binders and...
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
Is Erasca Inc. (NASDAQ:ERAS) the Best Biotech Penny Stock to Buy According to Hedge Funds?
We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Erasca Inc. (NASDAQ:ERAS) stands against other biotech penny stocks. Peter Marks’s departure from the FDA has left innovators concerned regarding the current state of the […]
Should You Consider Adding Marathon Petroleum Corporation (MPC) to Your Portfolio?
Oakmark Funds, advised by Harris Associates, released its “Oakmark Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund’s investor class returned 1.14% in the first quarter, compared to a -4.27% return for the S&P 500 Index. The fund has returned 12.76% since its inception compared to the index […]
ERAS Stock Earnings: Erasca Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Erasca (NASDAQ:ERAS) just reported results for the second quarter of 2024.Erasc...
Is Geron Corp. (NASDAQ:GERN) the Best Biotech Penny Stock to Buy According to Hedge Funds?
We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Geron Corp. (NASDAQ:GERN) stands against other biotech penny stocks. Peter Marks’s departure from the FDA has left innovators concerned regarding the current state of the […]
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential...
Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results
Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3...
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference
SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering,...
ERAS Stock Earnings: Erasca Misses EPS for Q2 2024
ERAS stock results show that Erasca missed analyst estimates for earnings per share the second quarter of 2024.
ERAS Stock Earnings: Erasca Misses EPS for Q1 2024
ERAS stock results show that Erasca missed analyst estimates for earnings per share the first quarter of 2024.
Erasca Reports Third Quarter 2024 Business Updates and Financial Results
Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized...
Erasca to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering,...
ERAS Stock Earnings: Erasca Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Erasca (NASDAQ:ERAS) just reported results for the fourth quarter of 2023.Erasc...
ERAS Stock Earnings: Erasca Beats EPS for Q4 2023
ERAS stock results show that Erasca beat analyst estimates for earnings per share the fourth quarter of 2023.
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise
Positive preliminary Phase 1b SEACRAFT-1 data for naporafenib plus trametinib reinforce therapeutic potential in NRASm melanoma and further support ongoing...
Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor Erasca is also evaluating naporafenib plus trametinib in the ongoing...
Erasca Reports Second Quarter 2024 Business Updates and Financial Results
In-licensed potential best-in-class pan-RAS molecular glue ERAS-0015 and potential first-in-class pan-KRAS inhibitor ERAS-4001 with a goal of expanding...
Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering,...
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors ...
Erasca Announces Pricing of Underwritten Offering of Common Stock
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering,...
ERAS Stock Earnings: Erasca Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Erasca (NASDAQ:ERAS) just reported results for the first quarter of 2024.Erasca...
Erasca Reports First Quarter 2024 Business Updates and Financial Results
Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private...
Erasca Reports First Quarter 2024 Business Updates and Financial Results
Erasca Announces $45 Million Oversubscribed Private Placement Financing
Funding from new and existing investors extends anticipated cash runway into H2 2026...
Erasca Announces $45 Million Oversubscribed Private Placement Financing
Funding from new and existing investors extends anticipated cash runway into H2 2026
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts...